Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained ...

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

Alnylam Pharmaceuticals Inc (ALNY) reports strong financial performance with significant growth in TTR franchise and ...

Christine Lindenboom; Chief Corporate Communications Officer; Alnylam Pharmaceuticals. Yvonne Greenstreet; Chief Executive Officer, Director; Alnylam Pharmaceuticals ...

The approvals of Onpattro, Givlaari, Oxlumo, and Leqvio combined with several partnerships have bolstered Alnylam's cash balance, and the company concluded fiscal 2024 with $2.69 billion in cash, cash ...

Discover Alnylam Pharmaceuticals' robust Q1 2025 earnings, highlighted by a 28% revenue growth and the successful launch of AMVUTTRA for ...

In its 10-Q report, Alnylam Pharmaceuticals stated that as of March 31, 2025, it had an accumulated deficit of $7.35 billion ...

With attention focused on their recently approved drugs for transthyretin amyloid cardiomyopathy (ATTR-CM), there was a ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,333.42 today based on a ...

Alnylam Pharmaceuticals (ALNY) reported $594.19 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 20.2%. EPS of -$0.01 for the same period compares to -$0.

Alnylam Pharmaceuticals (ALNY) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.16 per share a year ago. These ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based company said ...